False
September 1, 2026
7 min read
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
August 31, 2026
4 min read
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
August 31, 2026
4 min read
New approaches to oligonucleotide production, mRNA design, and supply chain control could help turn promising nucleic acid therapies into scalable commercial products
August 27, 2026
9 min read
Why preserving samples is a scientific, regulatory, and operational challenge – and what’s at risk when it goes wrong
False